NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis $2.21 +0.01 (+0.45%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$2.21 0.00 (-0.09%) As of 10/1/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsNews and TrendsOwnershipSEC Filings About Can-Fite BioPharma Stock (NYSE:CANF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Can-Fite BioPharma alerts:Sign Up Key Stats Today's Range$2.19▼$2.2550-Day Range$2.16▼$3.5852-Week Range$2.14▼$12.73Volume34,550 shsAverage Volume984,853 shsMarket Capitalization$2.36 millionP/E RatioN/ADividend YieldN/APrice Target$44.00Consensus RatingModerate Buy Company Overview Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company developing orally administered small-molecule drugs for inflammatory, metabolic, liver and cancer-related diseases. The company’s research is based primarily on compounds that target the A3 adenosine receptor, a receptor believed to play a role in regulating immune and inflammatory responses. Can-Fite’s lead candidates include piclidenoson, also known as CF101, which has been studied for conditions such as rheumatoid arthritis and psoriasis, and namodenoson, also known as CF102, which is being developed for liver-related diseases including metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma. The company has also investigated additional applications for its A3 adenosine receptor platform, including potential treatments for other inflammatory, oncological and metabolic disorders. Founded in 1994, Can-Fite conducts research and clinical development activities in Israel and internationally, including through studies involving patients and regulatory interactions in the United States and other markets. The company was founded by Dr. Pnina Fishman, who has served as its chief executive officer and has been associated with the development of its A3 adenosine receptor-based platform. Can-Fite’s products remain in clinical development and are not broadly marketed as approved commercial therapies.AI Generated. May Contain Errors. Read More Can-Fite BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreCANF MarketRank™: Can-Fite BioPharma scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCan-Fite BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialCan-Fite BioPharma has a consensus price target of $44.00, representing about 1,891.0% upside from its current price of $2.21.Amount of Analyst CoverageCan-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.Read more about Can-Fite BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CANF. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment-0.83 News SentimentCan-Fite BioPharma has a news sentiment score of -0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Can-Fite BioPharma this week, compared to 2 articles on an average week.Search Interest5 people have searched for CANF on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by Institutions21.00% of the stock of Can-Fite BioPharma is held by institutions.Read more about Can-Fite BioPharma's insider trading history. Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CANF Stock News HeadlinesHC Wainwright Has Bearish Forecast for CANF FY2026 EarningsOctober 1 at 6:12 AM | americanbankingnews.comCan-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver TransplantationSeptember 9, 2026 | globenewswire.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. | Paradigm Press (Ad)Can-Fite Reports Q2 2026 Results As Liver Cancer Survival Exceeds ExpectationsSeptember 8, 2026 | rttnews.comCan-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer StudySeptember 8, 2026 | globenewswire.comCan-Fite BioPharma Announces $4 Million Warrant ExerciseSeptember 2, 2026 | finance.yahoo.comCan-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer StudySeptember 2, 2026 | benzinga.comCan-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross ProceedsSeptember 2, 2026 | globenewswire.comSee More Headlines CANF Stock Analysis - Frequently Asked Questions How have CANF shares performed this year? Can-Fite BioPharma's stock was trading at $4.00 at the beginning of the year. Since then, CANF stock has decreased by 44.8% and is now trading at $2.21. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) announced its earnings results on Tuesday, November, 30th. The company reported ($38.00) EPS for the quarter, missing the consensus estimate of ($18.00) by $20.00. The firm earned $0.25 million during the quarter. When did Can-Fite BioPharma's stock split? Can-Fite BioPharma shares reverse split before market open on Monday, January 5th 2026.The 1-20 reverse split was announced on Tuesday, December 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, January 4th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Can-Fite BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE). Company Calendar Last Earnings11/30/2021Today10/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CANF's financial health is in the Yellow zone, according to TradeSmith. CANF has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:CANF CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees5Year FoundedN/APrice Target and Rating Average Price Target for Can-Fite BioPharma$44.00 High Price Target$80.00 Low Price Target$8.00 Potential Upside/Downside+1,891.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick RatioN/A Sales & Book Value Annual Sales$405 thousand Price / Sales5.84 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.26Miscellaneous Outstanding Shares1,070,000Free FloatN/AMarket Cap$2.36 million OptionableNot Optionable Beta1.12 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:CANF) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersThey're not telling you how bad this could getValuations are stretched to levels seen only a handful of times in the past century, while a growing debt spir...Parkview Capital Group | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
